CLINICAL_TRIALS ClinicalTrials.gov record update

A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03495921
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:12.239633+00:00
Published At: 2023-04-26T00:00:00+00:00
Record Updated At: 2023-04-26
Results Posted At: 2023-04-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ewing Sarcoma", "Ewing Family of Tumors", "Ewing\u0027s Tumor Metastatic", "Ewing\u0027s Sarcoma Metastatic", "Ewing\u0027s Tumor Recurrent", "Rare Diseases", "Sarcoma", "Neoplasms, Connective and Soft Tissue", "Neoplasms by Histologic Type", "Neoplasms, Bone Tissue", "Neoplasms, Connective Tissue", "Sarcoma, Ewing", "Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-04-26"
protocolSection.identificationModule.nctId: "NCT03495921"
protocolSection.identificationModule.officialTitle: "A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing\u0027s Sarcoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-04-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.